Brain Imaging of Intranasal Oxytocin Treatment in Autism

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Autism Spectrum Disorders
Interventions
DRUG

Oxytocin

"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."

Trial Locations (1)

27517

The University of North Carolina at Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of North Carolina, Chapel Hill

OTHER